Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't

TheMotleyFool 
0 0 21.07.17
2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't
 
2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't

Exelixis (NASDAQ: EXEL) is without question one of the hottest biotech stocks on the market. We're talking about a stock that has more than tripled in value in just the last 12 months and has soared over 70% so far this year. Exelixis is, simply put, a fantastic growth stock.

But Wall Street thinks Incyte (NASDAQ: INCY) is an even better growth stock. Analysts project faster earnings growth over the next few years for Incyte and think the stock price will increase more in the next year than Exelixis' share price will. 

Is Wall Street right that Incyte is a better growth stock than Exelixis? Here are two reasons why the answer is "yes" -- and one why the experts could be wrong.

Continue reading


Source: Fool.com

Exelixis Inc. Stock

€23.05
-1.510%
A loss of -1.510% shows a downward development for Exelixis Inc..
The stock is an absolute favorite of our community with 21 Buy predictions and no Sell predictions.
As a result the target price of 26 € shows a slightly positive potential of 12.8% compared to the current price of 23.05 € for Exelixis Inc..
Show more
Like: 0
EXEL
Share

Comments

Not a member yet? Sign up for free!